Uptake and transport of a novel anticancer drugdelivery system: Lactosyl-norcantharidin-associated N-trimethyl chitosan nanoparticles across intestinal Caco-2 cell monolayers

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 1921-1930

  Guan, Min ^a   Zhu, Qiao Ling ^a   Liu, Yang ^a   Bei, Yong Yan ^a   Gu, Zong Lin ^a   Zhang, Xue Nong ^a   Zhang, Qiang ^b  

^a SOOCHOW UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Caco 2 cell; Lac NCTD; Lac NCTD TMC NPs; Transport

Indexed keywords

CHITOSAN; DRUG CARRIER; LACTOSYL NORCANTHARIDIN; MULTIDRUG RESISTANCE PROTEIN; NANOPARTICLE; NORCANTHARIDIN; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VERLUKAST;

ACCURACY; ARTICLE; ATOMIC FORCE MICROSCOPY; CANCER CELL CULTURE; CELL STRAIN CACO 2; CELL TRANSFER; CELL TRANSPORT; CELLULAR DISTRIBUTION; COLORECTAL CARCINOMA; CONTROLLED STUDY; CROSS LINKING; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; NANOENCAPSULATION; PARTICLE SIZE; PH; REACTION TIME; TEMPERATURE SENSITIVITY; ZETA POTENTIAL;

BICYCLO COMPOUNDS, HETEROCYCLIC; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CHITOSAN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CARRIERS; ENDOCYTOSIS; HUMANS; HYDROGEN-ION CONCENTRATION; LACTOSE; NANOPARTICLES; PARTICLE SIZE; TEMPERATURE;

EID: 84870342662     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S30034     Document Type: Article

References (32)

1. Li Y, Huang G, Diakur J, Wiebe LI. Targeted delivery of macromolecular drugs: asialoglycoprotein receptor (ASGPR) expression by selected hepatoma cell lines used in antiviral drug development. Curr Drug Deliv. 2008;5(4):299-302.
2. Morell AG, Irvine RA, Sternlieb I, Scheinberg IH, Ashwell G. Physical and chemical studies on ceruloplasmin. V. Metabolic studies on sialic acid-free ceruloplasmin in vivo. J Biol Chem. 1968;243(1):155-159.
3. Hu ZH, Liu Y, Zhang L, et al. Preparation of a novel liver-targeting nanoparticle of norcantharidin derivative and evaluation of its antitumor activity. J Exp Nanosci. 2011;6(2):183-199.
4. Chew JL, Wolfowicz CB, Mao HQ, Leong KW, Chua KY. Chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen, Der p 1 for oral vaccination in mice. Vaccine. 2003;21(21-22): 2720-2729.
5. Wu Y, Yang WL, Wang CC, Hu JH, Fu SK. Chitosan nanoparticles as a novel delivery system for ammonium glycyrrhizinate. Int J Pharm. 2005;295(1-2):235-245.
6. Amidi M, Mastrobattista E, Jiskoot W, Hennink WE. Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Delivery Rev. 2010;62(1):59-82.
7. Yamashita S, Tanaka Y, Endoh Y, et al. Analysis of drug permeation across Caco-2 monolayer: implication for predicting in vivo drug absorption. Pharm Res. 1997;14(4):486-491.
8. Calvo P, Remuñan-López C, Vila-Jato JL, Alonso MJ. Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer NPs as novel carriers for proteins and vaccines. Pharm Res. 1997;14(10): 1431-1436.
9. Yang ZQ, Xu J, Pan P, Zhang XN. Preparation of an alternative freezedried PH-sensitive cyclosporine A nanoparticle formulation and its pharmacokinetic profile in rats. Pharmazie. 2009;64(1):26-31.
10. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem. 1976;72:248-254.
11. Huang M, Ma Z, Khor E, Lim LY. Uptake of FITC-chitosan nanoparticles by A549 cells. Pharm Res. 2002;19(1):1488-1494.
12. Hu M, Chen J, Zhu Y, Dantzig AH, Stratford RE Jr, Kuhfeld MT. Mechanism and kinetics of transcellular transport of a new beta-lactam antibiotic loracarbef across an intestinal epithelial membrane model system (Caco-2). Pharm Res. 1994;11(10):1405-1413.
13. Sun H, Pang KS. Permeability, transport, and metabolism of solutes in Caco-2 cell monolayers: a theoretical study. Drug Metab Dispos. 2008;36(1):102-123.
14. Reza MS, Quadir MA, Haider SS. Comparative evaluation of plastic, hydrophobic and hydrophilic polymers as matrices for controlled-release drug delivery. J Pharm Pharm Sci. 2003;6(2):282-291.
15. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Delivery Rev. 2004;56(11):1649-1659.
16. Meschini S, Molinari A, Calcabrini A, Citro G, Arancia G. Intracellular localization of the antitumour drug adriamycin in living cultured cells: a confocal microscopy study. J Micros. 1994;176(Pt 3):204-210.
17. Kotzé AF, Luessen HL, de Leeuw BJ, de Boer AG, Verhoef JC, Junginger HE. Comparison of the effect of different chitosan salts and N-trimethyl chitosan chloride on the permeability of intestinal epithelial cells (Caco-2). J Control Release. 1998;51(1):35-46.
18. Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev. 2001;46(1-3):27-43.
19. Dantzig AH, Hoskins JA, Tabas LB, et al. Association of intestinal peptide transport with a protein related to the cadherin superfamily. Science. 1994;264(5157):430-433.
20. Kool M, de Haas M, Scheffer GL, et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997;57(16):3537-3547.
21. van der Sandt IC, Blom-Roosemalen MC, de Boer AG, Breimer DD. Specif icity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. Eur J Pharm Sci. 2000;11(3):207-214.
22. Artursson P, Karlsson J. Correlation between oral drug absorption in humans and drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun. 1999;175(3): 880-885.
23. Nakagami T, Yasui-Furukori N, Saito M, Tateishi T, Kaneo S. Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Ther. 2005;78(1):43-51.
24. Haimeur A, Conseil G, Deeley RG, Cole SP. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab. 2004;5(1):21-53.
25. Varma MV, Asbokraj Y, Dey CS, Panchagnula R. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharm Res. 2003;48(4):347-359.
26. Martinez MN, Amidon GL. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol. 2002;42(6):620-643.
27. Collnot EM, Baldes C, Wempe MF, et al. Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity. Mol Pharm. 2007;4(3):465-474.
28. Florea BI, Thanou M, Junginger HE, Borchard G. Enhancement of bronchial octreotide absorption by chitosan and N-trimethyl chitosan shows linear in vitro/in vivo correlation. J Control Release. 2006;110(2): 353-361.
29. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2(1):48-58.
30. Hoggard KM, Varum KM, Issa M, et al. Improved chitosan-mediated gene delivery based on easily dissociated chitosan polyplexes of highly defined chitosan oligomers. Gene Ther. 2004;11(19):1441-1452.
31. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer. 2004;4(12):937-947.
32. Lai WF, Lin MC. Nucleic acid delivery with chitosan and its derivatives. J Control Release. 2009;134(3):158-168.